JIC
LGND icon

Joel Isaacson & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Joel Isaacson & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2
Closed – – 747
2016
Q1 		$0 Buy
+2
New +$122 ﹤0.01% 778

Other funds holding LGND

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Joel Isaacson & Co's LGND Position: Q2 2016 in Review

Joel Isaacson & Co sold out of Ligand Pharmaceuticals (LGND) in Q2 2016, closing a stake of 2 shares.

Joel Isaacson & Co first reported a position in LGND in Q1 2016 and held it in 1 quarter. The position peaked at $0 in Q1 2016. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2016.

  • Joel Isaacson & Co reported no remaining Ligand Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Joel Isaacson & Co sold 2 Ligand Pharmaceuticals shares in Q2 2016.
  • Joel Isaacson & Co first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Joel Isaacson & Co's Ligand Pharmaceuticals position peaked at $0 in Q1 2016.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2016.

Based on Joel Isaacson & Co's 13F filing for Q2 2016, filed 22 Jul 2016.